series-c-plus
Stage
1
Investors
About
Mendus is a clinical-stage biotechnology company developing immunotherapies to reduce tumor recurrence by harnessing the immune system to target residual cancer cells; its lead product vididencel is in clinical development. The company is headquartered in Stockholm, Sweden and is listed on Nasdaq Stockholm (ticker IMMU).
Explore Mendus's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.